• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Opko Health Successfully Tests a Bottom and Is Ready to Rise

A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.
By BRUCE KAMICH
Oct 08, 2020 | 07:55 AM EDT
Stocks quotes in this article: OPK

For his second Executive Decision segment of "Mad Money" Wednesday, host Jim Cramer spoke with Dr. Jon Cohen, executive chairman of BioReference Labs, the Covid-19 testing provider that is a part of Opko Health Inc. (OPK) .

BioReference Labs is the sole testing provider for both the NBA and NFL sports franchises. Cohen said it has performed more than 150,000 tests for the NBA, which is operating in a bubble in Florida. It also has conducted almost a half-million tests for the NFL, which is operating in multiple cities across the nation.

Cohen said while some have criticized his company for false positives, in reality it has implemented new protocols that automatically quarantine and retest borderline cases. That procedure, he said, has been working well as an extra step in keeping everyone safe.

In regard to the NFL, Cohen said it is likely moving to daily testing for everyone involved, especially given how long the incubation period is before positive results appear.

Let's check out the charts of OPK to see if anything is now incubating. 

 
We last reviewed the charts of OPK on Aug. 25 and wrote at the time, "Continue to avoid the long side of OPK. A decline into the $3.50-$3.00 area is possible." Now that prices re-based in the $3.00 area we can change our strategy.  
 
In this daily bar chart of OPK, below, we can see that prices found buying interest around $3.00 from late August through late September. A new rally has gotten underway, lifting prices above the declining 50-day moving average line. The slope of the 200-day moving average line is positive. The daily On-Balance-Volume (OBV) line made only a shallow dip in August and September as prices declined, telling us that longs largely stayed with their positions. The OBV line is restarting its climb as we write and tells us now that buyers are back. The Moving Average Convergence Divergence (MACD) oscillator crossed to the upside from below the zero line in September for a cover shorts buy signal and now is close to crossing the zero line for an outright go long message. 
 
 
 
In this weekly bar chart of OPK, below, we can see a bullish longer-term picture. Prices have turned upward again after a correction. OPK is above the rising 40-week moving average line. The weekly OBV line is strong and confirming the price action. The MACD oscillator has been narrowing toward a fresh buy signal. 
 
 
 
In this daily Point and Figure chart of OPK, below, we can see that prices reached their downside price objective.  
 
 
 
In this weekly close-only Point and Figure chart of OPK, below, we can see a potential price target in the $13.25 area. A traditional even-dollar amount was used for the scaling.  
 
 
Bottom line strategy: The correction in OPK is behind us and a new uptrend is underway. Traders could go long OPK in the $4.50-$4.00 area, risking a close below $3.50 for now. The $13.25 area is our price objective. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Health Care Equipment & Services | Healthcare | Life Sciences | Sports business | Mad Money | Executive Interview | Real Money | Sports | Coronavirus

More from Stocks

We're in the Jaws of a Bear Market, Whether You Want to Admit It or Not

James "Rev Shark" DePorre
Sep 26, 2023 4:24 PM EDT

Not even big caps like Microsoft or Apple could save the indexes -- but here's why some bad news could help shake out remaining false hopes.

Treasury Capitulation Is a Necessary Evil

Carley Garner
Sep 26, 2023 3:32 PM EDT

It is clear that interest rates are driving the ship, but that ship could be on the cusp of taking a major turn. If so, we can expect trend changes in other assets.

Williams-Sonoma Stock Jumps After Private Equity Investment

Bruce Kamich
Sep 26, 2023 1:34 PM EDT

Let's see what the charts are telling us now.

An Update on My Top Small-Cap Pick and What It Means for the Overall Market

James "Rev Shark" DePorre
Sep 26, 2023 11:30 AM EDT

The good news is that the corrective action is advancing and opportunities are developing.

Want to Bet That DraftKings Stock Has Rolled Over?

Bruce Kamich
Sep 26, 2023 10:00 AM EDT

Shares of the gambling site have weakened just as the football season gets into full swing.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:20 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading in Multiple Time Frames
  • 10:24 AM EDT BRUCE KAMICH

    This Could Get Messy

    A number of key stocks are getting close to import...
  • 01:41 PM EDT CHRIS VERSACE

    Latest AAP Podcast With Helene Meisler!

    Listen in as the Action Alerts PLUS podcast talks ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login